Management of Rosacea-Prone Skin: Evaluation of a Skincare Product Containing Ambophenol, Neurosensine, and La Roche-PosayThermal Spring Water as Monotherapy or Adjunctive Therapy
August 2013 | Volume 12 | Issue 8 | Original Article | 920 | Copyright © 2013
Sophie Seité PhD,a Florence Benech PharmD,b Sandrine Berdah PhD,b Muriel Bayer PharmD,b Sophie Veyrat PharmD,b Evelyne Segot PharmD PhD,b Marcela Sakalikova Mgr,c Lucia Gibejova Mgr,c Hana Zelenkova MD PhDc
aLa Roche-Posay Pharmaceutical Laboratories, Asnières, France
bL’Oréal Research and Innovation, Chevilly Larue, France
cDOST Svidnik, Private Clinic of Dermatovenerology, Svidnik, Slovakia
OBJECTIVE: The objective of these studies was to investigate whether a skincare product containing Ambophenol, Neurosensine, and La Roche-Posay thermal spring water formulated in a highly protective packaging can have an impact in the management of rosacea-prone skin subjects.
METHODS: Several studies were performed to evaluate the efficacy of this product in the management of rosacea prone skin, as either monotherapy or adjunctive therapy or to maintain the efficacy of a Metronidazole treatment. The first study was performed on 37 women aged 18-45 with added stage 2 erythro-couperosis, who applied test formula as monotherapy twice a day for 4 weeks. During a second study, a dermatological evaluation was performed on patients with stage I or II rosacea, a questionnaire containing information about patient characteristics, tolerance, clinical signs, symptoms and skin reactivity to “trigger factors” was completed by dermatologists at baseline and 2 months after treatment with the test formula as either monotherapy or adjunctive therapy. Finally, in a third study, 65 patients finishing a Metronidazole treatment applied once daily and the tested formula twice daily were divided into 2 groups using the test formula or vehicle control, twice a day for 8 weeks for the evaluation of efficacy as adjunctive therapy.
RESULTS: We noted that the test formula, as an adjunctive therapy, helped prolong the efficacy of a Metronidazole treatment. In monotherapy, there was a significant efficacy of the test formula associated with an excellent tolerance. A significant improvement of all the clinical signs and symptoms of rosacea and a reduction of the skin reactivity to "trigger factors" were shown.
CONCLUSIONS: These studies highlight the interest value and impact of a skincare product containing Ambophenol, Neurosensine, and La Roche-Posay thermal spring water formulated in a highly protective packaging in monotherapy or in combination with or after a therapeutic treatment in the management of patients suffering from rosacea.
J Drugs Dermatol. 2013;12(8):920-924.
Purchase Original Article
Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.
Download the original manuscript as it was published in the JDD.
Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.
To get access to JDD's full-text articles and archives, upgrade here.
Save an unformatted copy of this article for on-screen viewing.
Print the full-text of article as it appears on the JDD site.→ proceed | ↑ close
Rosacea is commonly described as a chronic inflammatory cutaneous disorder, primarily affecting the central facial zone (cheeks, chin, nose and central forehead). It is characterized by various cutaneous symptoms such as flush, erythema, telangiectasia, oedema, papules, pustules, etc. Rosacea occurs in both genders, but two to three times as many women as men are affected.1,2 It is most commonly apparent in pale-skinned, light-sensitive individuals of Celtic origin (skin types I and II according to Fitzpatrick) and less common in dark skinned individuals (skin type ≥ 3). Over 16 million Americans suffer from rosacea according to the National Rosacea Society3; its prevalence in Caucasian population is estimated in Europe to be between 5% (Southern Europe) and 10% (Northern Europe).1,4 Patients are most often diagnosed during their 30s to 50s5; overall, around 57% of cases are diagnosed in the under-50s.3 The first signs of the condition can occur in the form of flushing reactions before the age of 20. Rosacea starts in the vessels and the connective tissue of facial skin; it is characterized by a transient and persistent erythema and telangiectasia are regularly seen. Seborrhea is occasionally found and does not correlate with the severity of the condition.6
Diversity exists with regard to the classification of rosacea. It is clinically divided into a preliminary stage (pre-rosacea), three main stages of progression (stages I to III) and special forms.2,7,8 Based on this classification, standard treatment options have been proposed for the different subtypes. Rosacea does not only have a detrimental effect cosmetically, but due to its localization on the face, problems of disfigurement can arise leading to a distinct decrease in quality of life.9